XA-Novo: high-throughput mass spectrometry-based de novo sequencing technology for monoclonal antibodies and antibody mixtures - PubMed
3 hours ago
- #therapeutic antibodies
- #mass spectrometry
- #antibody sequencing
- XA-Novo is a high-throughput mass spectrometry-based de novo sequencing technology for monoclonal antibodies and antibody mixtures.
- It integrates a single-pot multi-enzymatic gradient digestion method with a beam search-based assembler (Fusion) to reconstruct full-length antibody sequences from bottom-up mass spectrometry data.
- XA-Novo outperforms commercial solutions in identification sensitivity, sequence completeness, and reconstruction accuracy.
- It successfully reconstructs six immunotherapeutic antibodies with unknown sequences, validated by in vitro/vivo assays to be functionally equivalent to commercial counterparts.
- XA-Novo achieves over 99.54% accurate sequence coverage in distinguishing mixed COVID-19 neutralizing antibodies, exceeding current assemblers' performance.
- The technology establishes a reliable, scalable, and broadly applicable workflow for routine antibody sequencing, accelerating antibody research and therapeutic development.